Evidence map›Paper›PMID 31537423›Full record

ArticleBioorganic & medicinal chemistry letters2019

SAR studies of 4-acyl-1,6-dialkylpiperazin-2-one arenavirus cell entry inhibitors.

Michael B Plewe, Landon R Whitby, Shibani Naik, Eric R Brown, Nadezda V Sokolova, Vidyasagar Reddy Gantla, Joanne York, Jack H Nunberg, Lihong Zhang, Birte Kalveram and 4 more

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Entry inhibitors as arenavirus antivirals.Frontiers in microbiology · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Michael B PleweArisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States.
Landon R WhitbyDepartment of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, United States.
Shibani NaikArisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States.
Eric R BrownArisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States.
Nadezda V SokolovaArisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States.
Vidyasagar Reddy GantlaArisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States.
Joanne YorkMontana Biotechnology Center, The University of Montana, Missoula, MT 59812, United States.
Jack H NunbergMontana Biotechnology Center, The University of Montana, Missoula, MT 59812, United States.
Lihong ZhangDepartment of Pathology, The University of Texas Medical Branch, Galveston, TX 77555, United States.
Birte KalveramDepartment of Pathology, The University of Texas Medical Branch, Galveston, TX 77555, United States.
Alexander N FreibergDepartment of Pathology, The University of Texas Medical Branch, Galveston, TX 77555, United States; Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch, Galveston, TX 77555, United States.
Dale L BogerDepartment of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, United States; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, United States.
Greg HenkelArisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States.
Ken McCormackArisan Therapeutics, 11189 Sorrento Valley Rd, Suite 104, San Diego, CA 92054, United States. Electronic address: kenm@arisanthera.com.
Arisan Therapeutics (United States) · USThe University of Texas Medical Branch at Galveston · USScripps Research Institute · USUniversity of Montana · US

Funding

Vascular stabilization as a broad theraprutic platform for biodefenseU54AI065357 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI PIERRO, DENNIS · 2005 to 2013
$77.5M
ANTITUMORE ANTIBIOTICS: STREPTONIGRIN AND LAVENDAMYCINR01CA042056 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BOGER, DALE L · 1985 to 2024
$10.6M
Pre-IND Development of an Arenavirus AntiviralR44AI112097 · NIAID · ARISAN THERAPEUTICS, INC. · PI HENKEL, GREGORY WILLIAM · 2016 to 2022
$6.0M
Structure-function studies of the tripartite Junin arenavirus GP-CR01AI074818 · NIAID · UNIVERSITY OF MONTANA · PI NUNBERG, JACK H · 2008 to 2012
$1.6M
Optimization of Arenavirus AntiviralsR43AI112097 · NIAID · ARISAN THERAPEUTICS, INC. · PI MCCORMACK, KEN J, PLEWE, MICHAEL BRUNO · 2014 to 2015
$600k
NCI NIH HHS R01 CA042056NIAID NIH HHS R01 AI074818NIAID NIH HHS R43 AI112097NIAID NIH HHS R44 AI112097NIAID NIH HHS U54 AI065357
6 · The paper itself

Abstract

Old World (Africa) and New World (South America) arenaviruses are associated with human hemorrhagic fevers. Efforts to develop small molecule therapeutics have yielded several chemical series including the 4-acyl-1,6-dialkylpiperazin-2-ones. Herein, we describe an extensive exploration of this chemotype. In initial Phase I studies, R

Indexed as

Antiviral AgentsArenavirusDose-Response Relationship, DrugMicrobial Sensitivity TestsMolecular StructurePiperazinesStructure-Activity RelationshipViral Envelope ProteinsAntiviral AgentsPiperazinesViral Envelope ProteinsArenavirusEntry inhibitorJuninLassaMachupoPiperazinone

Identifiers

PMID31537423
PMCPMC6803051
OpenAlexW2969448314

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.